Antibody paratopes can be added to the human repertoire by CRISPR-Cas9 editing of B lymphocytes using a strategy that allows for hypermutation and class switching of resulting B cell receptors.

An unbiased mutational screen decodes the molecular basis of phage receptor interactions, identifies key functional regions determining activity and host range, and demonstrates the potential for engineering therapeutic phages.

ePAC, a novel cancer vaccine utilizing a mammalian-derived virus-like particle to co-deliver neoantigens and CpG-ODN, demonstrates strong antitumor efficacy in mouse models.

COVID-19 CG is an open source web resource that allows vaccine, therapeutics, and diagnostics developers to track SARS-CoV-2 mutations and lineages by location and time.

Molecular dynamics simulation assisted engineering of recombinant soluble human ACE2 N-glycosylation by site-directed mutagenesis or glycosidase treatment yields a superior SARS-CoV-2 decoy receptor.

A new cross-species machine learning-based strategy is applied to find enhancers that specifically label parvalbumin neurons in the mouse and macaque.

A transcriptome-based pipeline (scAAVengr) quantifies and ranks competing adeno-associated viral vectors in primate retina, and mouse brain, heart, and liver, simultaneously and across all cell types, in the same animal, with single-cell resolution.

CLEVER enables the rapid manipulation and direct rescue of plus-strand RNA viruses with the shortest hands-on time to study viral variants of concern.

A new way to alter the genome of bacteriophages helps produce large libraries of variants, allowing these bacteria-killing viruses to be designed to target species harmful to human health.